Dermoscopy segmentation by application reveals distinct clinical priorities. Skin cancer detection dominates the market, accounting for ~52% of revenue, driven by rising melanoma incidence and regulatory emphasis on early diagnosis. Mole analysis follows at 28%, fueled by increasing demand for non-invasive diagnostics in cosmetic dermatology. Chronic skin conditions (e.g., psoriasis, eczema) represent 15%, leveraging dermoscopyโs role in monitoring treatment efficacy. Rarely, 5% is attributed to research and training applications, where advanced imaging aids in academic and technical development. This segmentation underscores the marketโs reliance on oncology-driven adoption, with secondary growth in routine dermatological care.